Ublituximab联合伊布替尼对比伊布替尼单药治疗复发/难治高危慢性淋巴细胞白血病(GENUINE):一项3期多中心开放标签随机试验
GENUINE研究纳入126例复发/难治且伴17p缺失、11q缺失或TP53突变的高危慢性淋巴细胞白血病患者,随机接受ublituximab联合伊布替尼或伊布替尼单药。
要点
- 最常见3-4级不良事件为中性粒细胞减少、贫血和腹泻,联合组中性粒细胞减少19% vs 12%。
- 联合组2例因不良事件死亡(心脏骤停、衰竭),均判定与治疗无关。
核心结论
- 在复发/难治高危慢性淋巴细胞白血病患者中,ublituximab联合伊布替尼较伊布替尼单药显著提高总缓解率,且未影响伊布替尼单药的安全性特征。
研究设计与样本
- 随机、3期、多中心、开放标签研究(GENUINE),在美国和以色列119家诊所进行。
- 纳入年龄≥18岁、复发/难治且至少伴17p缺失、11q缺失或TP53突变之一的慢性淋巴细胞白血病患者,既往至少接受过一种治疗,ECOG体能状态≤2。
- 126例患者按1:1随机分配至ublituximab联合伊布替尼组(n=64)或伊布替尼单药组(n=62),按既往治疗线数(1线 vs ≥2线)分层。
- 主要终点为独立评审委员会评估的总缓解率(意向治疗人群),安全性在至少接受一剂治疗的患者中评估。
主要发现
- 安全性分析纳入117例患者(联合组59例,单药组58例),大多数不良事件为1或2级。
- 最常见3-4级不良事件:中性粒细胞减少(联合组11例[19%] vs 单药组7例[12%])、贫血(5例[8%] vs 5例[9%])、腹泻(6例[10%] vs 3例[5%])。
- 最常见严重不良事件:肺炎(联合组6例[10%] vs 单药组4例[7%])、房颤(4例[7%] vs 1例[2%])、脓毒症(4例[7%] vs 1例[2%])、发热性中性粒细胞减少(3例[5%] vs 1例[2%])。
- 联合组2例因不良事件死亡(心脏骤停和衰竭),均判定与治疗无关;单药组5例因不良事件死亡,其中心脏骤停判定与治疗相关。
关键数值与推荐
- 总缓解率定义为根据2008年国际CLL工作组标准达到部分缓解、完全缓解或完全缓解伴骨髓恢复不完全的患者比例。
- 伊布替尼口服420 mg每日一次,所有周期。
- Ublituximab静脉给药,28天为一周期:第1周期第1天≤150 mg,第2天750 mg,第8天和第15天900 mg;第2-6周期第1天900 mg;第6周期后每3周期900 mg。
临床怎么用
- 对于复发/难治高危(17p缺失、11q缺失或TP53突变)慢性淋巴细胞白血病患者,可考虑在伊布替尼基础上联合ublituximab以提高缓解率。
- 联合治疗时需监测中性粒细胞减少、贫血、腹泻、肺炎、房颤、脓毒症和发热性中性粒细胞减少等不良事件。
局限性
- 研究为开放标签设计,患者和研究者的治疗分配未设盲。
- 因患者入组缓慢,方案修订将共同主要终点改为单一主要终点总缓解率。
- 最终分析时总缓解率的评估基于意向治疗人群,但部分患者可能未接受治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic lymphocytic leukaemia and high-risk features have poorer outcomes on ibrutinib than those without high-risk features. The aim of this study was to assess the benefit of adding ublituximab, an anti-CD20 monoclonal antibody, to ibrutinib therapy in this population. METHODS: We did a randomised, phase 3, multicentre study (GENUINE) of patients aged 18 years or older with relapsed or refractory chronic lymphocytic leukaemia with at least one of 17p deletion, 11q deletion, or TP53 mutation, at 119 clinics in the USA and Israel. Eligible patients had received at least one previous chronic lymphocytic leukaemia therapy and had an Eastern Cooperative Oncology Group performance status of 2 or lower. We randomised patients (1:1) using permuted block randomisation with a block size of four and stratified by previous lines of therapy (one vs two or more) to receive ibrutinib alone or ibrutinib in combination with ublituximab. Treatment allocation was not masked to patients or investigators. Ibrutinib was given orally daily at 420 mg for all cycles. Ublituximab was given intravenously in 28-day cycles, with increasing doses during cycle 1 (≤150 mg on day 1, 750 mg on day 2, and 900 mg on days 8 and 15) and continuing at 900 mg on day 1 of cycles 2-6. After cycle 6, ublituximab was given at 900 mg every three cycles. The study was initially designed with co-primary endpoints of progression-free survival and overall response rate but due to protracted patient accrual, the protocol was amended to have a single primary endpoint of independent review committee-assessed overall response rate (defined as the proportion of patients who had a partial response, complete response, or complete response with incomplete marrow recovery according to the 2008 International Workshop on CLL criteria) in the intention-to-treat population. Safety was evaluated in the population of patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT02301156, and the final analysis is presented. FINDINGS: 224 patients were assessed for eligibility, of whom 126 patients were enrolled and randomly assigned to receive ublituximab plus ibrutinib (n=64) or ibrutinib alone (n=62) between Feb 6, 2015, and Dec 19, 2016. After a median follow-up of 41·6 months (IQR 36·7-47·3), the overall response rate was 53 (83%) of 64 patients in the ublituximab plus ibrutinib group and 40 (65%) of 62 patients in the ibrutinib group (p=0·020). 117 patients, including 59 in the ublituximab plus ibrutinib group and 58 in the ibrutinib group, received at least one dose of treatment and were included in safety analyses. Most adverse events were grade 1 or 2. The most common grade 3 and 4 adverse events were neutropenia (11 [19%] patients in the ublituximab plus ibrutinib group and seven [12%] in the ibrutinib group), anaemia (five [8%] and five [9%]), and diarrhoea (six [10%] and three [5%]). The most common serious adverse events were pneumonia (six [10%] in the ublituximab plus ibrutinib group and four [7%] in the ibrutinib group), atrial fibrillation (four [7%] and one [2%]), sepsis (four [7%] and one [2%]), and febrile neutropenia (three [5%] and one [2%]). Two patients in the ublituximab plus ibrutinib group died due to adverse events (one cardiac arrest and one failure to thrive), neither of which were treatment-related. Five patients in the ibrutinib group died due to adverse events, including one cardiac arrest, one cerebral infarction, one intracranial haemorrhage, one Pneumocystis jirovecii pneumonia infection, and one unexplained death; the death due to cardiac arrest was considered to be treatment-related. INTERPRETATION: The addition of ublituximab to ibrutinib resulted in a statistically higher overall response rate without affecting the safety profile of ibrutinib monotherapy in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia. These findings provide support for the addition of ublituximab to Bruton tyrosine kinase inhibitors for the treatment of these patients. FUNDING: TG Therapeutics.
引用
- Sharman JP, Brander DM, Mato AR, et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021. PMID: 33631112. doi:10.1016/S2352-3026(20)30433-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。